Budget Impact Analysis Of Health Care Interventions

The first of its kind for budget-impact analysis, this comprehensive guide provides clear and concise instructions for evaluating the impact that new pharmaceuticals will have on the budget for a specific jurisdiction. The book demonstrates how to create a budget-impact analysis using a simple six-step process that is consistent with current guidelines for these analyses. Examples and exercises for each chapter afford an opportunity to practice the six-step process in practical applications. The book progresses from a framework for budget impact analyses to an in-depth review of components and how to develop and present these in software applications and reports. Critical considerations such as uncertainty analysis and validation, and considerations for alternate interventions, such as vaccines and diagnostics, are also covered. This book is a “must have” for the builder and budget holder, with builders benefiting from instructions to identify and estimate all necessary variables and budget holders receiving a guide to what should be included in the analyses they assess.

In this book the authors explore the state of the art on efficiency measurement in health systems and international experts offer insights into the pitfalls and potential associated with various measurement techniques. The authors show that: - The core idea of efficiency is easy to understand in principle - maximizing valued outputs relative to inputs, but is often difficult to make operational in real-life situations - There have been numerous advances in data collection and availability, as well as innovative methodological approaches that give valuable insights into how efficiently health care is delivered - Our simple analytical framework can facilitate the development and interpretation of efficiency indicators.

"IEA, International Epidemiological Association, Welcome Trust."

To order please visit https://onlineacademiccommunity.uvic.ca/press/books/ordering/

Mental, neurological, and substance use disorders are common, highly disabling, and associated with significant premature mortality. The impact of these disorders on the social and economic well-being of individuals, families, and societies is large, growing, and underestimated. Despite this burden, these disorders have been systematically neglected, particularly in low- and middle-income countries, with pitifully small contributions to scaling up cost-effective prevention and treatment strategies. Systematically compiling the substantial existing knowledge to address this inequity is the central goal of this volume. This evidence-base can help policy makers in resource-constrained settings as they prioritize programs and interventions to address these disorders.

Defining the value in health care and elaborating appropriate value-propositions for health care beneficiaries poses numerous empirical and normative challenges. Different methods of Health Technology Assessments (HTAs) embedded in various interdisciplinary approaches of defining the value of health care have been established in recent years. Current initiatives aim to develop and combine transnational attempts to define an overall acceptable range for value-based healthcare interventions. In this book international scholars with background in medicine, philosophy, health-economics and further disciplines, who participated in an interdisciplinary conference in 2019 combine in-depth analyses with reflections informed by multidisciplinary debates on a pressing issue in healthcare.

Economic evidence contributes to the organization of efficient health care and to the promotion of the best health outcomes within budgetary constraints. Despite some inherent limitations, its importance has increased across the globe amid growing concern over the rise in the costs of health care. In the United States, this is coupled with a Federal presence in health policy regulation and financing, leading to reconsideration of the role of economic and clinical evidence in decisionmaking by leading actors. In the United States, the comparative effectiveness of medical interventions undergoes rigorous evaluation. However, there is limited use of economic data in comparing health interventions and creating rational policy in the United States when compared with best practices in other high-income countries. This is despite repeated calls for integrating economic evaluation data routinely into the U.S. health care policy process. The economic evidence about health care interventions refers to such characteristics as cost, price elasticity, efficiency, and value data, either collected empirically or synthesized in economic modeling.19 Economic evaluation combines economic data, such as cost-utility ratios, net monetary benefit, and total budget impact estimates, leading to summary economic information on the characteristics of interventions. Examples are a cost-utility ratio, a cost-effectiveness ratio, the net monetary benefit, or a total budget impact estimate. Cost-effectiveness analysis is a specific type of formalized economic evaluation commonly used in the consideration of economic evidence in health care. It typically focuses on the incremental changes in costs and health benefits after the introduction of a medical intervention as compared to an initial situation, and is meant to aid rational decisionmaking. This type of analysis has become the most common mechanism for generating economic evidence in decisionmaking both inside and outside the United States. Evidence from systematic reviews of clinical outcomes presently plays an established role in determining the comparative effectiveness of medical interventions and is useful in developing clinical practice guidelines, making efficacy-based coverage decisions, and in formulating general health policy. The processes of searching for and summarizing the results of studies have been standardized with the goal of demonstrating clinical efficacy and effectiveness in a uniform way, using all available information. Systematic reviews may also be valuable in evaluating the economic impact of introducing interventions. Around the world, standardized guides have been developed to conduct state-of-the-art economic evaluations, to include economic data in systematic reviews, to systematically review economic data, and to use systematic reviews to inform economic evaluations. In the United States, however, the systematic inclusion of economic outcomes and the review of economic data in systematic reviews to inform health policy is not standardized as is already the case for clinical outcomes.